Johnson & Johnson Beats Q4 Sales and Profit Estimates on Cancer Drug Sales
Johnson & Johnson (NYSE: JNJ), fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular (NASDAQ: ITCI), reported fourth-quarter […]
Johnson & Johnson Beats Q4 Sales and Profit Estimates on Cancer Drug Sales Read More »
